Beam Therapeutics Inc (BEAM) is -4.91% away from 50-day simple Moving Average despite all headwinds

Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Tuesday, up 0.30% from the previous trading day, before settling in for the closing price of $16.62. Over the past 52 weeks, BEAM has traded in a range of $13.52-$35.25.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 412.30% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -0.42%. With a float of $89.62 million, this company’s outstanding shares have now reached $100.56 million.

In an organization with 483 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.06%, operating margin of -677.47%, and the pretax margin is -609.18%.

Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 10.88%, while institutional ownership is 88.04%. The most recent insider transaction that took place on Apr 01 ’25, was worth 104,122. In this transaction Chief Legal Officer of this company sold 5,674 shares at a rate of $18.35, taking the stock ownership to the 117,294 shares. Before that another transaction happened on Apr 01 ’25, when Company’s CEO sold 30,663 for $18.35, making the entire transaction worth $562,684. This insider now owns 986,249 shares in total.

Beam Therapeutics Inc (BEAM) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around -0.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.84% during the next five years compared to -20.88% drop over the previous five years of trading.

Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators

Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 8.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.37.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.61, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.64 in one year’s time.

Technical Analysis of Beam Therapeutics Inc (BEAM)

Let’s dig in a bit further. During the last 5-days, its volume was 1.91 million. That was inferior than the volume of 1.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.26%. Additionally, its Average True Range was 1.16.

During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 14.48%, which indicates a significant decrease from 32.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.84% in the past 14 days, which was lower than the 82.60% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $17.53, while its 200-day Moving Average is $23.49. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $17.82. Second resistance stands at $18.97. The third major resistance level sits at $19.61. If the price goes on to break the first support level at $16.03, it is likely to go to the next support level at $15.39. The third support level lies at $14.24 if the price breaches the second support level.

Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats

The company with the Market Capitalisation of 1.68 billion has total of 100,557K Shares Outstanding. Its annual sales at the moment are 63,520 K in contrast with the sum of -376,740 K annual income. Company’s last quarter sales were recorded 7,470 K and last quarter income was -109,270 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.